New Delhi, 13 April (IANS). Veteran Indian pharma company Glenmark Pharmaceuticals, Sun Pharmaceutical Industries and Jides have recalled several drugs from the US market due to manufacturing problems. This information was given in the latest report of US Food and Drug Administration (FDA).
Mumbai -based Glenmark has recalled more than 25 products in the US due to non -presence of medicines current Good Manufacturing Practice (CGMP).
The American branch of the New Jersey company, Glenmark Pharmaceuticals Inc., is withdrawing several drugs, including propafenon hydrochloride extended-relief capsules and solifenasin Saksinet Tablet.
Other drugs called back include Voriconazole tablets, lacosamide tablets, frovatripton Saxannet Tablet and Roofinamide Tablet. The company started Class II recall on 13 March this year.
According to the USFDA, Class II recall is released when the use of the product can cause temporary or medical health problems. However, the chances of serious health problems are low.
Another Indian pharma company Sun Pharmaceutical Industries is also recalling its products in the US. Its American unit Sun Pharmaceutical Industries Inc. has called back 13,700 bottles of Gabapantin Capsule.
These capsules are used for treatment and prevention of seizures in people suffering from epilepsy.
This class III recall began on March 4, 2025. Class III recall is considered the least serious.
In addition, Zidas, a subsidiary of Zidas, Zidas Pharmaceuticals (USA) Inc. has recalled 3,144 bottles of Chlorpromzine hydrochloride tablet.
These pills are used to treat mental health conditions such as schizophrenia and bipolar disorder.
The USFDA stated that the recall was done due to the presence of impurities called N-Nitroso-Desamethill chlorpromzine, which was found to be higher than the acceptable range. The company started Class II recall on 3 April.
The USFDA regularly monitors the safety and quality of drugs sold in the US and ensures that drug manufacturers follow strict manufacturing standards.
-IANS
ABS/
